In the Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation (RE-DUAL PCI) trial as well as in the Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation (AUGUSTUS) trial, clopidogrel was the recommended P2Y12 inhibitor for patients with coronary artery disease treated with PCI, but the treating physician was allowed to prescribe a more potent P2Y12 inhibitor if deemed indicated. Here, P2RY12 is linked to coronary artery disorder.